Pharmanex Cholestin public health benefit potential noted by Sen. Harkin in letter to FDA.
This article was originally published in The Tan Sheet
Executive Summary
CHOLESTIN PUBLIC HEALTH BENEFIT POTENTIAL NOTED BY SEN. HARKIN in a Jan. 16 letter to FDA. Tom Harkin (D-Iowa) suggests "the public health factor should be weighed heavily in any decision regarding implementation" of the Dietary Supplement Health & Education Act. "In this case, there appears to be considerable evidence and expert judgment that Cholestin can serve an important health promotion purpose." FDA is expected to make a decision in the near future on whether Pharmanex may continue to market the red yeast rice product as a dietary supplement for healthy cholesterol levels.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning